Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alimera Sciences Inc (NASDAQ:ALIM)

1.23
Delayed Data
As of Jun 30
 -0.05 / -3.91%
Today’s Change
1.21
Today|||52-Week Range
5.15
-49.17%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$57.7M

Company Description

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. It focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by C. Daniel Myers and David R. Holland and is headquartered in Alpharetta, GA.

Contact Information

Alimera Sciences, Inc.
6120 Windward Parkway
Alpharetta Georgia 30005
P:(678) 990-5740
Investor Relations:

Employees

Shareholders

Mutual fund holders6.60%
Individual stakeholders54.08%
Other institutional42.66%

Top Executives

Charles Daniel MyersChief Executive Officer & Director
Richard S. EiswirthPresident & Chief Financial Officer
Kenneth GreenChief Scientific Officer
Susan H. CaballaSenior VP-Regulatory & Technical Affairs
David R. HollandSenior Vice President-Sales & Marketing